The Food and Drug Administration approved Portola Pharmaceuticals Inc.'s (Nasdaq: PTLA) blood clot prevention drug Bevyxxa. Shares of the company surged $17.81 to close at $56.06.
FDA approves Portola's Bevyxxa
June 23, 2017 at 18:00 PM EDT
Photography by Christophe Tomatis